This convergent mechanism not only establishes Rac1 as a central therapeutic target but also redefines Peters anomaly pathogenesis through a shared axis of cytoskeletal dysregulation, offering novel insights into its etiology and treatment strategies. This evidence concerns the gene RAC1 and Peters anomaly.